BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York
on February 12th
BIO CEO & Investor Conference 2013
JERUSALEM -- January 31, 2013
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development
company, announced today that its Chief Executive Officer, Kinneret Savitsky,
Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be
presenting at the 2013 BIO CEO & Investor Conference in New York.
Dr. Savitsky and Mr. Serlin are scheduled to present at 2:00 P.M. EST on
Tuesday, February 12th.
A live Webcast of the presentation will be available on the BioLineRx Website
at http://www.biolinerx.com/default.asp?pageid=63&itemid=155. A replay will be
available one hour after the presentation ends and will be accessible for
three months following the presentation.
Investors or potential partners attending the conference that wish to meet
with Dr. Savitsky or Mr. Serlin for a one-on-one meeting should contact the
BIO Partnering Team at firstname.lastname@example.org.
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers has
completed Phase I. In addition, BioLineRx has eight products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase III)
and commercialization. For more information on BioLineRx, please visit
KCSA Strategic Communications
Garth Russell, 1-212-896-1250
Todd Fromer, 1-212-896-1250
Tsipi Haitovsky, Public Relations
Press spacebar to pause and continue. Press esc to stop.